• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket

    12/11/23 7:59:28 AM ET
    $ACRX
    $BMEA
    $CI
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRX alert in real time by email

    Shares of Green Giant Inc. (NASDAQ:GGE) fell sharply in pre-market trading after announcing a proposed public offering.

    Green Giant shares dipped 37.1% to $0.1599 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • NextPlay Technologies, Inc. (NASDAQ:NXTP) shares rose 62.8% to $0.6841 in pre-market trading. NextPlay Technologies recently received notice from Nasdaq stating that it did not comply with listing rule.
    • Onconova Therapeutics, Inc. (NASDAQ:ONTX) shares gained 29.3% to $0.83 in pre-market trading. Onconova Therapeutics' preclinical narazaciclib data at SABCS highlighted differentiated anti-tumor activity v. other CDK4/6i's.
    • Macy's, Inc. (NYSE:M) rose 19.1% to $20.71 in pre-market trading. An investor consortium has tabled a $5.8 billion bid to acquire Macy's, in an attempt to privatize the iconic department store chain.
    • AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) shares rose 17.7% to $0.8576 in pre-market trading after falling more than 4% on Friday.
    • NaaS Technology Inc. (NASDAQ:NAAS) gained 14.9% to $2.39 in pre-market trading. NaaS Technology recently announced termination of proposed Charge Amps acquisition.
    • Corvus Pharmaceuticals, Inc.(NASDAQ:CRVS) gained 14.6% to $2.20 in pre-market trading. Corvus Pharmaceuticals presented new interim soquelitinib data from its Phase 1/1b T Cell lymphoma trial.
    • NuZee, Inc. (NASDAQ:NUZE) shares surged 12.1% to $2.69 in pre-market trading after declining 10% on Friday.
    • The Cigna Group (NYSE:CI) shares gained 11.6% to $288.88 in pre-market trading. Cigna has withdrawn from its proposed merger with Humana Inc. (NYSE:HUM).
    • Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) shares rose 11.5% to $0.85 in pre-market trading after falling over 5% on Friday.
    • JanOne Inc. (NASDAQ:JAN) shares climbed 8.8% to $0.58 in pre-market trading after jumping 14% on Friday.

    Losers

    • RiskOn International, Inc. (NASDAQ:ROI) shares fell 25.9% to $0.1401 in pre-market trading. RiskOn International recently said Kurt Flygare has been appointed Chief Executive Officer of GuyCare Management, Inc., a subsidiary of GuyCare, Inc.
    • Near Intelligence, Inc. (NASDAQ:NIR) shares fell 21.1% to $0.12 in pre-market trading. Near Intelligence filed for Chapter 11 protection and entered into agreement to sell its business.
    • iSun, Inc. (NASDAQ:ISUN) shares fell 20.8% to $0.1520 in pre-market trading after declining around 7% on Friday.
    • X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) fell 17.6% to $0.7248 in pre-market trading. X4 Pharmaceuticals announced presentation of additional data from mavorixafor Phase 2 trial in chronic neutropenia at ASH 2023.
    • Purple Biotech Ltd. (NASDAQ:PPBT) shares fell 17.5% to $0.9160 in pre-market trading.
    • Biomea Fusion, Inc. (NASDAQ:BMEA) shares fell 17.2% to $13.99 in pre-market trading. Biomea Fusion announced near doubling the percentage of patients with durable HbA1c reduction in the 200 mg dose cohorts.
    • eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) fell 15.1% to $0.4412 in pre-market trading. eFFECTOR Therapeutics, on Friday, announced new interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer.
    • African Agriculture Holdings Inc. (NASDAQ:AAGR) fell 12.6% to $2.01 in pre-market trading after dipping 49% on Friday.
    • Cyngn Inc. (NASDAQ:CYN) fell 9.5% to $0.1918 in pre-market. Cyngn shares fell 47% on Friday after the company announced pricing of a $5 million public offering of common stock.

     

    Now Read This: Oracle, Casey's General Stores And 3 Stocks To Watch Heading Into Monday

     

    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $BMEA
    $CI
    $CRVS

    CompanyDatePrice TargetRatingAnalyst
    Macy's Inc
    $M
    3/19/2026$25.00 → $20.00Market Perform
    Telsey Advisory Group
    The Cigna Group
    $CI
    3/12/2026$358.00Mkt Perform → Outperform
    Bernstein
    X4 Pharmaceuticals Inc.
    $XFOR
    3/9/2026$12.00Buy
    Guggenheim
    Humana Inc.
    $HUM
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Macy's Inc
    $M
    1/14/2026$27.00Buy
    Jefferies
    Biomea Fusion Inc.
    $BMEA
    1/13/2026$8.00Buy
    Rodman & Renshaw
    Humana Inc.
    $HUM
    1/7/2026$290.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $ACRX
    $BMEA
    $CI
    $CRVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

    Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

    4/29/24 2:36:51 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $BMEA
    $CI
    $CRVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Gagnon Robert E.

    3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)

    3/18/26 6:06:33 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dai Zhen

    3 - NaaS Technology Inc. (0001712178) (Issuer)

    3/18/26 1:55:33 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 3 filed by new insider Zhang Wei (Nmn)

    3 - NaaS Technology Inc. (0001712178) (Issuer)

    3/18/26 1:54:03 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    $ACRX
    $BMEA
    $CI
    $CRVS
    SEC Filings

    View All

    SEC Form 10-K filed by Processa Pharmaceuticals Inc.

    10-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)

    3/18/26 4:05:57 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Macy's Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Macy's, Inc. (0000794367) (Filer)

    3/18/26 7:06:04 AM ET
    $M
    Department/Specialty Retail Stores
    Consumer Discretionary

    Cyngn Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Cyngn Inc. (0001874097) (Filer)

    3/17/26 4:30:26 PM ET
    $CYN
    EDP Services
    Technology

    $ACRX
    $BMEA
    $CI
    $CRVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Macy's, Inc. and Macy's Return to Annual Comparable Sales Growth; Fourth Quarter and Fiscal Year 2025 Results Exceed Guidance

    Bold New Chapter gained traction across all nameplates during fourth quarter, driven by go-forward stores and digital Bloomingdale's achieved its best holiday performance on record in the fourth quarter Macy's expands strategic initiatives to 75 additional stores, creating "Reimagine 200" for 2026 Macy's, Inc. (NYSE:M) today reported financial results for the fourth quarter and fiscal year 2025 and provided fiscal year 2026 guidance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318878750/en/ Fourth Quarter 2025 Highlights Macy's, Inc. net sales of $7.6 billion exceeded guidance. Macy's, Inc. comparable sales1 gr

    3/18/26 6:55:00 AM ET
    $M
    Department/Specialty Retail Stores
    Consumer Discretionary

    Cyngn Inc. Announces Closing of $9.65 Million Registered Direct Offering, Priced at the Market Under Nasdaq Rules

    MOUNTAIN VIEW, Calif., March 17, 2026 /PRNewswire/ -- Cyngn Inc. (NASDAQ:CYN) today announced the closing of its previously announced registered direct offering for the purchase and sale of approximately $9.65 million of shares of Common Stock and pre-funded warrants at a price of $1.93 per share of Common Stock. A single institutional investor acquired greater than ninety percent of the offering, with a high-net-worth individual purchasing the remaining percent. The entire transaction was priced at the market under Nasdaq rules. The offering consisted of the sale of 5,000,000 s

    3/17/26 10:48:00 AM ET
    $CYN
    EDP Services
    Technology

    X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for the Treatment of WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway through 2028 - BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. "Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver

    3/17/26 7:15:00 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $BMEA
    $CI
    $CRVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Macy's with a new price target

    Telsey Advisory Group reiterated coverage of Macy's with a rating of Market Perform and set a new price target of $20.00 from $25.00 previously

    3/19/26 7:55:45 AM ET
    $M
    Department/Specialty Retail Stores
    Consumer Discretionary

    The Cigna Group upgraded by Bernstein with a new price target

    Bernstein upgraded The Cigna Group from Mkt Perform to Outperform and set a new price target of $358.00

    3/12/26 8:38:26 AM ET
    $CI
    Medical Specialities
    Health Care

    Guggenheim initiated coverage on X4 Pharmaceuticals with a new price target

    Guggenheim initiated coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    3/9/26 9:13:19 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $BMEA
    $CI
    $CRVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    Officer Erdtmann Rainer M bought $42,999 worth of shares (30,000 units at $1.43), increasing direct ownership by 4% to 723,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/15/25 4:15:04 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim CEO Hitchcock Michael J.M. bought $99,180 worth of shares (100,000 units at $0.99), increasing direct ownership by 667% to 115,000 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/4/25 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $BMEA
    $CI
    $CRVS
    Financials

    Live finance-specific insights

    View All

    Macy's, Inc. and Macy's Return to Annual Comparable Sales Growth; Fourth Quarter and Fiscal Year 2025 Results Exceed Guidance

    Bold New Chapter gained traction across all nameplates during fourth quarter, driven by go-forward stores and digital Bloomingdale's achieved its best holiday performance on record in the fourth quarter Macy's expands strategic initiatives to 75 additional stores, creating "Reimagine 200" for 2026 Macy's, Inc. (NYSE:M) today reported financial results for the fourth quarter and fiscal year 2025 and provided fiscal year 2026 guidance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318878750/en/ Fourth Quarter 2025 Highlights Macy's, Inc. net sales of $7.6 billion exceeded guidance. Macy's, Inc. comparable sales1 gr

    3/18/26 6:55:00 AM ET
    $M
    Department/Specialty Retail Stores
    Consumer Discretionary

    Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 d

    3/5/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyngn Announces Date for 2025 Fourth Quarter and Year-End Financial Results

    MOUNTAIN VIEW, Calif., March 5, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) will announce its 2025 fourth quarter and year-end financial results for the period ended December 31, 2025, on Wednesday, March 25, 2026, after the close of market. The financial results will be available on the Cyngn website under "News & Events" at https://investors.cyngn.com/.  The Company will not host an earnings call.About CyngnCyngn develops and deploys autonomous vehicle technology for industrial organizations like manufacturers and logistics companies. The Company addresses significant challenges f

    3/5/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    $ACRX
    $BMEA
    $CI
    $CRVS
    Leadership Updates

    Live Leadership Updates

    View All

    Purple Biotech Announces CEO Transition

    Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing next-generation cancer therapies, today announced that Gil Efron, Chief Executive Officer, will step down from his role as CEO effective August 2026. Mr. Efron will remain actively involved with the Company, transitioning to lead corporate development and continuing as a member of the Board of Directors. In this new capacity, he will focus on identifying strategic initiatives, partnerships, and support the Company's financing activities as needed

    3/13/26 8:04:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Cigna Group Announces President & COO Brian Evanko to Succeed David M. Cordani as Chief Executive Officer

    Cordani to retire as chief executive officer on July 1, 2026, and will serve as executive chair of The Cigna Group Board of DirectorsEvanko elected to the company's Board of DirectorsCompany reaffirms 2026 Financial OutlookBLOOMFIELD, Conn., March 3, 2026 /PRNewswire/ -- The Cigna Group (NYSE: CI) today announced that David M. Cordani will retire as chief executive officer effective July 1, 2026, and become executive chair of The Cigna Group's Board of Directors. Brian Evanko, current president and chief operating officer, will succeed Cordani as CEO. Throughout his tenure—inclu

    3/3/26 7:30:00 AM ET
    $CI
    Medical Specialities
    Health Care

    Cyngn Adds Former Lyft Exec, Ran Makavy, to Board

    Mr. Makavy led growth at Lyft and later ran its core platform through the 2019 IPO. He also founded Snaptu, which was acquired by Facebook in 2011.MOUNTAIN VIEW, Calif., Feb. 25, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today announced the appointment of Ran Makavy to its Board of Directors. He brings senior growth and platform leadership experience from Lyft and Facebook, where he helped scale large technology businesses through high-growth phases. At Lyft, Makavy built the growth team which was responsible for getting more drivers and riders to use Lyft and getting them to use

    2/25/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    $ACRX
    $BMEA
    $CI
    $CRVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NaaS Technology Inc.

    SC 13G/A - NaaS Technology Inc. (0001712178) (Subject)

    11/14/24 9:58:25 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by NaaS Technology Inc.

    SC 13G/A - NaaS Technology Inc. (0001712178) (Subject)

    11/14/24 5:31:20 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Purple Biotech Ltd.

    SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

    11/14/24 5:21:29 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care